astrazeneca glp 1 GLP-1 pill shows promise in obesity, diabetes trials astrazeneca oral glp 1 ADA

Dual and triple receptor agonists, such as tirzepatide and retatrutide, provide additional benefits by targeting several pathways involved in energy regulation, resulting in greater weight loss and better metabolic results than typical GLP-1 RAs

Indirectly : by improving serum hormone levels

New mechanisms for weight loss are continually being explored, offering new potential drug targets from cannabinoid receptor blockers, nucleotide-binding domain, leucine-richcontaining family, pyrin domaincontaining-3 (NLRP3) inhibitors, free fatty acid receptor 2 (FFA2) inhibitors and gene-editing RNA therapy

Ng ang s dg s ph k n bi

A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions